[Remote] Medical Science Liaison/Sr. Medical Science Liaison, Oncology - Northeast Region at Corcept Therapeutics

Remote

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, HealthcareIndustries

Skills

Key technologies and capabilities for this role

OncologyCortisol ModulationGynecological OncologyScientific DiscussionsThought Leader EngagementInsight GatheringScientific EducationHealthcare Professional Education

Questions & Answers

Common questions about this position

What region does this MSL role cover?

This role covers the Northeast Region, including Vermont, Connecticut, Massachusetts, Rhode Island, New Hampshire, and Maine.

What are the main responsibilities of the Oncology MSL?

Responsibilities include engaging in scientific discussions with thought leaders in gynecological oncology, educating healthcare professionals on cortisol modulation, developing relationships with oncology organizations, capturing insights from the medical community, and supporting clinical trials and scientific communications.

What is the team like for this Oncology MSL position?

The initial oncology MSL team was formed in 2024 with highly experienced and motivated MSLs focused on thought leader engagement, insight gathering, and scientific education, forming a high-performing team well-respected in the cross-functional Oncology Business Unit.

What salary or compensation is offered for this role?

This information is not specified in the job description.

What makes a strong candidate for this MSL position?

Strong candidates will have high standards of scientific, clinical, and technical expertise in oncology, particularly gynecological oncology, experience in thought leader engagement, and the ability to maintain ethical and professional standards.

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free